scholarly journals 145: Rethinking the cystic fibrosis care team: A novel telehealth structure promotes interdisciplinary care and improves understanding of team member roles

2021 ◽  
Vol 20 ◽  
pp. S72-S73
Author(s):  
D. Miller ◽  
G. Drake ◽  
L. Mees ◽  
K. Barker ◽  
C. Hobart ◽  
...  
NEJM Catalyst ◽  
2021 ◽  
Vol 2 (9) ◽  
Author(s):  
Kenneth Lam ◽  
Erika L. Price ◽  
Megha Garg ◽  
Nate Baskin ◽  
Megan Dunchak ◽  
...  

Pharmacy ◽  
2019 ◽  
Vol 7 (2) ◽  
pp. 34 ◽  
Author(s):  
Olufunmilola Abraham ◽  
Ashley Morris

Cystic fibrosis (CF) is one of the most common life-threatening, genetic conditions. People with CF follow complex, time-consuming treatment regimens to manage their chronic condition. Due to the complexity of the disease, multidisciplinary care from CF Foundation (CFF)-accredited centers is recommended for people with CF. These centers include several types of healthcare professionals specializing in CF; however, pharmacists are not required members. The purpose of this study was to identify the outpatient care needs of people living with CF that pharmacists could address to improve their quality of care. Healthcare members from a CFF accredited center and pharmacists were recruited to participate in semi-structured, audio-recorded interviews. Prevalent codes were identified and data analysis was conducted, guided by the systems engineering initiative for patient safety (SEIPS) model. The objective was to understand the medication and pharmacy-related needs of patients with CF and care team perspectives on pharmacists providing support for these patients. From the themes that emerged, pharmacists can provide support for people living with CF (medication burden, medication access, medication education) and the CF care team (drug monitoring and adherence, prior authorizations and insurance coverage, refill history). Pharmacists are well-positioned to address these difficulties to improve quality of care for people living with cystic fibrosis.


2018 ◽  
Vol 110 (4) ◽  
pp. 378-383 ◽  
Author(s):  
Oh Samuel ◽  
Jacqueise M. Unonu ◽  
Kierra Dotson ◽  
Soon Park ◽  
Richard Parker ◽  
...  

2014 ◽  
Vol 49 (10) ◽  
pp. 971-977 ◽  
Author(s):  
Maria Socorro Rayas ◽  
Donna Beth Willey-Courand ◽  
Jane Lockwood Lynch ◽  
Jesus Ramon Guajardo

1978 ◽  
Vol 12 ◽  
pp. 446-446
Author(s):  
Bernice J Lubin ◽  
A Harold Lubin ◽  
Judy L Bonner

Author(s):  
Corinne Muirhead ◽  
Wendy Palmrose ◽  
Michelle Condren ◽  
Shannon Rotolo ◽  
Rebecca Pettit ◽  
...  

Introduction: To help open the clinician dialogue regarding cannabis use in persons with CF in the U.S., we aimed to describe current practices of use assessment and documentation processes related to cannabis. Methods: A cross sectional, anonymous survey study was distributed via email to CF directors and coordinators and to the Cystic Fibrosis Foundation (CFF) listservs of nurse, pharmacist, dietitian, social worker and psychology care team members. The survey tool included multiple choice, scaled and open ended items, which assessed participants’ awareness of current cannabis laws in their state, prescribing practices for medical marijuana, screening and documentation practices, knowledge of and what indications participants believe cannabis and cannabidiol (CBD) could be beneficial. Data was analyzed using descriptive statistics. Results: There were 282 survey participants, with majority as providers (28%) and social workers (29%), representing all U.S. regions. Participants varied in terms of frequency of evaluating cannabis use, with 15.4% “always,” 48.4% “sometimes,” and 41% “rarely” or “never” asking about it. Regarding recreational versus medical cannabis use, 55.4% and 62.5% reported documentation of each type in the medical record, respectively. Participants reported appetite, pain, and nausea as the top three advocated indications for use. About 35% and 72% of participants felt “slightly” or “not at all” prepared to answer patient/family questions about cannabis and CBD, respectively. Conclusions: The approach to cannabis use assessment, documentation, and education across CF care centers is variable. There is a need for care team and patient/caregiver education materials about cannabis/CBD and CF.


2019 ◽  
Vol 45 (5) ◽  
pp. 39-45
Author(s):  
Chunying Chen ◽  
Yingying Huang ◽  
Caixia Liu ◽  
Ying Xu ◽  
Lingyan Zheng ◽  
...  

2017 ◽  
Vol 35 (31_suppl) ◽  
pp. 171-171
Author(s):  
Girish Chandra Kunapareddy ◽  
Joseph Hooley ◽  
Leticia Varella ◽  
Christa Poole ◽  
Helen Tackitt ◽  
...  

171 Background: Due to complexity of disease and treatments, oncology patients have among the highest hospitalization rate, especially towards End of Life (EOL). In our cancer institute, just 6% of all discharged patients accounted for >40% of unplanned readmissions, and continue to be highest risk of future admissions, ICU stay, ED visits, overuse of chemotherapy and under use of hospice care. We hypothesized that developing individualized care plans (ICP) for this high-utilization group will provide guidance in the complex care they require to reduce unnecessary and aggressive medical services. Methods: An Interdisciplinary Care Team (ICT) was created consisting of palliative medicine and oncology physicians, social workers, care coordinators, and nurses. On a bimonthly basis, patients with at least two unplanned hospital readmissions over the last 60 days were identified. ICPs were created using a team-based approach with parallel input from patient’s primary outpatient providers. Results: A total of 36 patients, 226 hospitalizations, and 163 ED visits were evaluated over a 6-month period, with an average number of hospitalizations of 1.08 per patient month (ppm). After implementation of ICP, hospitalizations decreased to 0.23 ppm, with an average length of stay decrease from 7.17 to 4.06 days per admission. Average ED visits decreased from 0.58 to 0.34 ppm, and the average number of unplanned readmissions decreased from 0.43 to 0.13 ppm. Of the 10 patients expired since creation of ICP, 8 utilized hospice care, while 2 patients died in an ICU. Average time to death from creation of ICP was 72 days among this cohort, while time to death from last exposure to chemotherapy was 58 days. Conclusions: Creation of individualized care plans for high-utilizing cancer patients decreased number of hospitalizations, ED visits, unplanned readmissions, and length of stay. A dedicated focus from a team of experts, beyond disease biology, on a unique patient situation may result in improved patient experience with decreased aggressiveness of care at EOL and overall resource utilization.


Sign in / Sign up

Export Citation Format

Share Document